Table 1.
Clinical characteristics of the patients.
| Characteristics | No. (%) |
|---|---|
| Gender | |
| Male | 95 (76.6) |
| Female | 29 (23.4) |
| Age (year) | |
| <64 | 61 (49.2) |
| ≥64 | 63 (50.8) |
| Smoking history | |
| Ever | 53 (42.7) |
| Never | 71 (57.3) |
| BMI | |
| <18.5 | 8 (6.5) |
| 18.5–24.9 | 87 (70.2) |
| >24.9 | 29 (23.4) |
| Histology | |
| Adenocarcinoma | 84 (67.7) |
| Squamous carcinoma | 37 (29.8) |
| Other histology a) | 3 (2.4) |
| TNM stage | |
| III | 30 (24.2) |
| IV | 94 (75.8) |
| ECOG PS | |
| 0 | 37 (29.8) |
| 1 | 87 (70.2) |
| Chemotherapy regimen | |
| Platinum + pemetrexed | 81 (65.3) |
| Platinum + paclitaxel | 19 (15.3) |
| Platinum + gemcitabine | 15 (12.1) |
| Platinum + docetaxel | 9 (7.3) |
| Response to chemotherapy | |
| PR | 25 (20.2) |
| SD | 75 (60.5) |
| PD | 24 (19.4) |
| Targeted therapy b) | |
| No | 88 (71.0) |
| Yes | 36 (29.0) |
| Immunotherapy c) | |
| No | 107 (86.3) |
| Yes | 17 (13.7) |
| Antiangiogenic therapy d) | |
| No | 89 (71.8) |
| Yes | 35 (28.2) |
| PFS (IQR) months | 8.0 (5.0-18.0) |
| OS median (IQR) months | 17.0 (12.0-30.0) |
| At Baseline | |
| SII (IQR) | 809.2 (513.5-1064.2) |
| PNI (IQR) | 47.7 (44.2-52.9) |
| After 4 cycles | |
| SII (IQR) | 450.2 (287.6-718.9) |
| PNI (IQR) | 43.9 (40.5-52.3) |
a) Other histology was pathologically confirmed as non-small cell lung cancer, but the specific was unclear. bcd) All three regimens were used when progression or relapse has followed a minimum of 4 cycles of first-line platinum-based chemotherapy.